BNP Paribas Développement crosses a threshold at MEDICELL

MEDINCELL, a company listed on Euronext Paris, received a letter from BNP Paribas Développement. BNP Paribas Développement stated that it had crossed below the 5% threshold of voting rights. This change was triggered by an increase in the total number of voting rights held by MEDINCELL. The financial giant now holds 3.04% of the share capital and 4.63% of the voting rights, with 1,090,688 shares, compared to a total of 46,631,214 voting rights held by the company.

This information is significant for the market, as it reflects a shift in BNP Paribas Développement's influence on the voting power at MEDINCELL. This change could affect certain future decisions within the company.